Human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine is under clinical development by Beijing Health Guard Biotechnology and currently in Phase III for Human Papillomavirus Infections. According to GlobalData, Phase III drugs for Human Papillomavirus Infections have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine overview

Vaccine is under development for the prevention of vaginal cancer, cervical cancer, vulvar cancer, anal cancer, genital warts (condyloma acuminatum), vulvar intraepithelial neoplasia, anal intraepithelial neoplasia, vaginal intraepithelial neoplasia, human papillomavirus (HPV) associated cancer, human papillomavirus infections, penile cancer and cervical intraepithelial neoplasia. It comprises of antigens of HPV types 6,11,16,18,31,33,45,52,58. The drug candidate is administered by intramuscular route.

Beijing Health Guard Biotechnology overview

Beijing Health Guard Biotechnology (BHGB) is a research and development of papillomavirus and anti-tumor drugs based on structural design of recombinant protein-based biological products. BHGB is headquartered in Beijing, China.

For a complete picture of Human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.